Saracatinab    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
85Idiopathic interstitial pneumonia1

85. Idiopathic interstitial pneumonia    [ 514 clinical trials,   377 drugs,   (DrugBank: 108 drugs),   97 drug target genes,   204 drug target pathways]
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 514 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04598919
(ClinicalTrials.gov)
November 1, 202015/9/2020Saracatinib in the Treatment of Idiopathic Pulmonary FibrosisUse of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)Drug: Saracatinab;Drug: PlaceboNational Jewish HealthYale University;Icahn School of Medicine at Mount Sinai;AstraZeneca;National Center for Advancing Translational Science (NCATS)Recruiting40 YearsN/AAll100Phase 1;Phase 2United States